Humana Inc. (NYSE:HUM) Shares Sold by Avantax Advisory Services Inc.

Avantax Advisory Services Inc. decreased its position in Humana Inc. (NYSE:HUM) by 43.8% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 1,842 shares of the insurance provider’s stock after selling 1,433 shares during the period. Avantax Advisory Services Inc.’s holdings in Humana were worth $467,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in HUM. Farther Finance Advisors LLC raised its position in shares of Humana by 4.0% during the 4th quarter. Farther Finance Advisors LLC now owns 2,103 shares of the insurance provider’s stock worth $533,000 after purchasing an additional 81 shares during the last quarter. Wealthfront Advisers LLC raised its holdings in shares of Humana by 130.7% in the fourth quarter. Wealthfront Advisers LLC now owns 31,408 shares of the insurance provider’s stock worth $7,969,000 after acquiring an additional 17,793 shares during the last quarter. River Road Asset Management LLC purchased a new stake in shares of Humana in the fourth quarter valued at $3,465,000. Pzena Investment Management LLC boosted its stake in shares of Humana by 44.0% during the fourth quarter. Pzena Investment Management LLC now owns 3,609,382 shares of the insurance provider’s stock valued at $915,736,000 after acquiring an additional 1,103,132 shares during the last quarter. Finally, Marathon Trading Investment Management LLC purchased a new stake in Humana during the 4th quarter worth about $1,162,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Insider Buying and Selling at Humana

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the transaction, the insider now directly owns 8,181 shares in the company, valued at $2,096,463.06. This represents a 31.16 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.37% of the stock is owned by insiders.

Humana Stock Down 0.2 %

NYSE HUM opened at $266.33 on Monday. The stock has a market cap of $32.14 billion, a PE ratio of 26.77, a P/E/G ratio of 2.05 and a beta of 0.57. The business has a 50 day moving average price of $271.33 and a two-hundred day moving average price of $276.25. Humana Inc. has a fifty-two week low of $213.31 and a fifty-two week high of $406.46. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68.

Humana (NYSE:HUM) last released its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. As a group, sell-side analysts predict that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be issued a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a yield of 1.33%. The ex-dividend date of this dividend is Friday, March 28th. Humana’s dividend payout ratio is currently 35.58%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on HUM shares. Truist Financial boosted their price objective on shares of Humana from $260.00 to $290.00 and gave the company a “hold” rating in a research report on Monday, January 6th. Cantor Fitzgerald reissued a “neutral” rating and set a $290.00 price target on shares of Humana in a research note on Wednesday, February 12th. Morgan Stanley lowered their price objective on Humana from $301.00 to $285.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 12th. Royal Bank of Canada reiterated an “outperform” rating and set a $283.00 target price on shares of Humana in a research report on Wednesday, February 12th. Finally, StockNews.com cut Humana from a “buy” rating to a “hold” rating in a report on Tuesday, March 18th. Eighteen equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, Humana currently has a consensus rating of “Hold” and an average price target of $285.68.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.